×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Colorectal Cancer
Feature Video
Colorectal cancer is one of the more commonly diagnosed cancers among both men and women today. Despite the fact that it most exclusively affects older persons, colorectal cancer is continuing to be diagnosed in younger and younger patients. CURE Connections wants to answer any questions you might have when it comes to managing colorectal cancer. This program includes information as shared by an expert physician, and personal accounts from patients and their caretakers who have dealt with colorectal cancer.
Thomas K. Weber, M.D., FACS
Tumor testing can lead to different treatment choices and better outcomes.
Sarah DeBord
As a parent facing cancer, we just want to know that our children will emerge on the other side of our diagnosis and be alright.
Jason M. Broderick
The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor Braftovi (encorafenib), the MEK inhibitor Mektovi (binimetinib), and the EGFR inhibitor Erbitux (cetuximab) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC) following one or two prior lines of treatment in the metastatic setting.
TARA HAELLE
Scientists have spent 35 years seeking ways to disable RAS, a gene that’s mutated in many cancer types. Now, they’re moving closer to solutions.
Brielle Urciuoli
The FDA approved Opdivo plus Yervoy to treat a certain subset of patients with metastatic colorectal cancer.
Kristie L. Kahl
The American Cancer Society issued an updated guideline recommendation that now calls for screening to begin at age 45 for individuals at average risk for colorectal cancer.
Kristie L. Kahl
Understanding one’s biomarkers, such as microsatellite stable (MSS) or instable (MSI) status in tumors, is key in understanding how a patient with colorectal cancer may be treated.
Jessica Skarzynski
Take a look at the top five CURE stories of June 2018 in this video.
Aaron Franke, M.D.
Recent research found that patients under 50 were less likely to have a treatment-determining biomarker than their older counterparts.
This year’s survey is expanded to better learn about the experience of caregivers, with a selection of questions specifically for them. The Alliance asks that just one caregiver per patient fill out the survey.